The acquisition will allow Nycomed to gain access to a number of biologic and protein-based drugs manudactured by Techpool.
Techpool has developed and launched a number of protein drugs, including Ulinastatin, a trypsin inhibitor, which is a compound used in the treatment of sepsis and multiple organ dysfunctions and Kallikrein, a serine protease used as a neuroprotective agent in the treatment of stroke.
Techpool said that it has filed for 35 patents, of which 17 have already been granted, including one US patent approval.
While Nycomed China and Techpool will be run as separate companies, as per the agreement value will be created through various forms of alliances between the two entities.
The two companies will continue to expand their footprint in China and will focus their efforts around five core brands Ulinastatin, Kallikrein, Pantoloc, Ebrantil and Actovegin.
Nycomed CEO Hakan Bjorklund said that the acquisition of the majority stake in Techpool provides them with an opportunity to strengthen their business in China.